Breaking News
Sort by:
Top Post
Roche’s Tecentriq Plus Avastin Reduced Risk of Cancer Returning in People with Certain Types of Adjuvant Liver Cancer in a Phase III Study
Roche has announced new data from the Phase III IMbrave050 study that show Tecentriq (atezolizumab) […]
PEP-Therapy and Institut Curie Announce First Patients Dosed in Phase I Clinical Trial of PEP-010 for the Treatment of Advanced Solid Tumors
PEP-Therapy, a clinical-stage biotechnology company developing cell penetrating peptides as targeted therapies in oncology, and […]
CN Bio Expands Service Offering to Support Oncology Drug Discovery
CN Bio, a leading Organ-on-a-chip Company (OOC) that designs and manufactures single- and multi-organ microphysiological […]
C-RAD and Accuray Sign Agreement to Enhance Radixact® System Breast Cancer Treatment Capabilities
C-RAD AB (NASDAQ Stockholm: CRAD B) and Accuray Incorporated (NASDAQ: ARAY) announced today they have signed […]
Enhertu Granted Breakthrough Therapy Designation in US for Patients with HER2-positive Metastatic Breast Cancer Treated with One or More Prior Anti-HER2-based Regimens
The Food and Drug Administration (FDA) has granted Enhertu (trastuzumab deruxtecan), Breakthrough Therapy Designation (BTD) in the […]
New Study Finds Freenome ’s Multiomics Approach Successful in Detecting Pancreatic Cancer
Freenome, a privately-held biotech company, presented new research today at the American Association of Cancer […]
Diaprost Licenses its Novel Theranostic Antibody, hu5A10, to Radiopharm Theranostics for Development in the Treatment and Diagnosis of Prostate Cancer
Diaprost announced today that it has agreed terms for an exclusive Licensing Agreement with Radiopharm […]
Artificial Intelligence Tool Improves Accuracy of Breast Cancer Imaging
A computer program trained to see patterns among thousands of breast ultrasound images can aid […]
Targovax Granted European Patent for ONCOS-102 in Combination with Chemotherapy
Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing immune activators to target hard-to-treat […]
Imfinzi Plus Chemotherapy Tripled Patient Survival at Three Years in the CASPIAN Phase III Trial in Extensive-stage Small Cell Lung Cancer
Updated results from the CASPIAN Phase III trial showed AstraZeneca’s Imfinzi (durvalumab) in combination with a choice […]
FDA Approves Tissue-Based NGS Companion Diagnostic for Takeda's Targeted Therapy for NSCLC Patients with EGFR Exon20 Insertion Mutations
The U.S. Food and Drug Administration (FDA) has granted premarket approval to Thermo Fisher Scientific‘s […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more